Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Highlights From ASH 2020 on Multiple Myeloma

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Two experts discuss results from key studies in multiple myeloma from the virtual Hematology 2020 meeting, including updated data on treatment options for newly diagnosed disease and an analysis of available agents for relapsed/refractory myeloma.
Shaji K. Kumar, MD
Sagar Lonial, MD
Released: March 12, 2021

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma.

Topics include:

  • Newly diagnosed multiple myeloma
  • Relapsed/refractory multiple myeloma
  • Anti-BCMA therapy: CAR T-cells
  • Anti-BCMA therapy: bispecific antibodies
  • Anti-BCMA therapy: antibody–drug conjugates
  • Novel targeted agents for relapsed/refractory multiple myeloma

Presenters:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast from a satellite symposia at the 2021 Hematology meeting on diagnosis and management of aTTP, from Clinical Care Options (CCO)

Ara Metjian, MD
Program Director
Paul Coppo, MD, PhD Marshall Mazepa, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: January 26, 2022 Expired: January 25, 2023

Free video from Clinical Care Options (CCO) featuring expert discussion of use of asparaginase-based treatments in young and older adults with acute lymphoblastic leukemia

Wendy Stock, MD
Program Director
Emily Curran, MD Dan Douer, MD person default Scott Howard, MD, MSc person default Stephen P. Hunger, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 24, 2022 Expired: January 23, 2023

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings